Table 7 Comparison of ARGs prevalence in this study with some studies in Iran and other regions of the world
Region | Year | Authors | Method | Sample size and origin | blaTEM | blaCTX-M | blaSHV | blaCMY |
|---|---|---|---|---|---|---|---|---|
This study | 2023 | Afshari et al | PCR | 106 E. coli isolates from 168 UTI cases | 89.6% | 44.3% | 6.6% | 0.94% |
Iran (Jiroft) | 2018 | Mashaiekhi et al | PCR | 181 E.coli isolates from UTI cases | 58% | NS | 33% | NS |
Iran | 2020 | Ghaderi et al | Systematic review | 68 studies on E. coli isolates from clinical cases | 51% | 45% | 37% | NS |
Iran | 2021 | Jabalameli et al | Systematic review | 61 studies on E. coli isolates from clinical cases | 27.6% | 31.2% | 9.8% | NS |
China | 2021 | Jia | PCR | 332 ESBL-producing and -uncertain E. coli isolates | NA | NA | NA | 0.3% |
Sri Lanka | 2022 | Perera et al | PCR | 422 Enterobacteriaceae isolates from UTIs | 25% | 33% | 8% | 15% |
South Africa | 2020 | Kubone et al | PCR | 26 E. coli isolates from 143 urine samples | 3.84% | 11.53% | 0% | NS |
Africa (East) | 2016 | Sonda et al | Meta-analysis | 4076 Enterobacteriaceae isolates | 16–55% | 70–88.5% | 3–64% | NA |
Nigeria | 2016 | Mohammed et al | PCR | 439 E. coli isolates from clinical specimens | 31.4% | 27.3% | 36.4% | NS |
Europe | 2019 | Sepp et al | WGS | 10,780 E.coli isolates from clinical cases | 54.9% | 77.5% | 21.4% | 7.9% |
US | 2019 | Mendes et al | NGS | 2751 E. coli isolates from blood and UTI cases | 0.3% | 87.6% | 0.3% | 7.8% |
USA | 2016 | Lob et al | Microarray and PCR | 181 ESBL-positive E. coli isolates from UTI cases | 3.3% | 91.7% | 2.2% | NA |
Canada | 2016 | Lob et al | Microarray and PCR | 74 ESBL-positive E. coli isolates from UTI cases | 1.5% | 87.8% | 2.9% | NA |